Tags

Type your tag names separated by a space and hit enter

Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
Expert Opin Biol Ther 2015; 15(5):641-50EO

Abstract

INTRODUCTION

Psoriatic arthritis (PsA) is a chronic inflammatory condition involving the spine, enthesis and peripheral joints, which is associated with psoriasis. PsA therapy varies from use of NSAIDs to disease-modifying anti-rheumatic agents (DMARDs). However, their use can represent a limitation in patients with concomitant hepatitis C virus (HCV) infection. In the last few decades, anti-TNF-α therapy has opened new horizons in the treatment of PsA. Hence, the purpose of this review is to explore the efficacy and safety of anti-TNF-α agents in PsA and concomitant HCV infection.

AREAS COVERED

We reviewed the available medical literature to find all cases of PsA and concomitant HCV infection treated with TNF-α inhibitors. We found a total of 38 cases of patients with PsA and concomitant HCV infection in therapy with anti-TNF-α agents.

EXPERT OPINION

The available literature, summarized in this review, still remains very limited. Data suggest that therapy with the anti-TNF-α agents, mainly etanercept and adalimumab, at least with short-term use, would appear efficacious and reasonably safe in the management of PsA patients with concomitant HCV infection. With regard to infliximab, efficacy and safety have been scarcely explored, whereas in the case of golimumab and certolizumab no report was found, may be due to their recent introduction on the market.

Authors+Show Affiliations

University of Padova, Department of Medicine DIMED, Rheumatology Unit , Via Giustiniani 2, 35128 Padova , Italy +39 049 8211206 ; +39 049 8214382 ; francescocaso1@yahoo.it.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25652590

Citation

Caso, Francesco, et al. "Current Evidence in the Field of the Management With TNF-α Inhibitors in Psoriatic Arthritis and Concomitant Hepatitis C Virus Infection." Expert Opinion On Biological Therapy, vol. 15, no. 5, 2015, pp. 641-50.
Caso F, Cantarini L, Morisco F, et al. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther. 2015;15(5):641-50.
Caso, F., Cantarini, L., Morisco, F., Del Puente, A., Ramonda, R., Fiocco, U., ... Costa, L. (2015). Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opinion On Biological Therapy, 15(5), pp. 641-50. doi:10.1517/14712598.2015.1011616.
Caso F, et al. Current Evidence in the Field of the Management With TNF-α Inhibitors in Psoriatic Arthritis and Concomitant Hepatitis C Virus Infection. Expert Opin Biol Ther. 2015;15(5):641-50. PubMed PMID: 25652590.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. AU - Caso,Francesco, AU - Cantarini,Luca, AU - Morisco,Filomena, AU - Del Puente,Antonio, AU - Ramonda,Roberta, AU - Fiocco,Ugo, AU - Lubrano,Ennio, AU - Peluso,Rosario, AU - Caso,Paolo, AU - Galeazzi,Mauro, AU - Punzi,Leonardo, AU - Scarpa,Raffaele, AU - Costa,Luisa, Y1 - 2015/02/04/ PY - 2015/2/6/entrez PY - 2015/2/6/pubmed PY - 2015/11/17/medline KW - TNF-α inhibitors KW - adalimumab KW - etanercept KW - hepatitis C virus infection KW - psoriatic arthritis SP - 641 EP - 50 JF - Expert opinion on biological therapy JO - Expert Opin Biol Ther VL - 15 IS - 5 N2 - INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory condition involving the spine, enthesis and peripheral joints, which is associated with psoriasis. PsA therapy varies from use of NSAIDs to disease-modifying anti-rheumatic agents (DMARDs). However, their use can represent a limitation in patients with concomitant hepatitis C virus (HCV) infection. In the last few decades, anti-TNF-α therapy has opened new horizons in the treatment of PsA. Hence, the purpose of this review is to explore the efficacy and safety of anti-TNF-α agents in PsA and concomitant HCV infection. AREAS COVERED: We reviewed the available medical literature to find all cases of PsA and concomitant HCV infection treated with TNF-α inhibitors. We found a total of 38 cases of patients with PsA and concomitant HCV infection in therapy with anti-TNF-α agents. EXPERT OPINION: The available literature, summarized in this review, still remains very limited. Data suggest that therapy with the anti-TNF-α agents, mainly etanercept and adalimumab, at least with short-term use, would appear efficacious and reasonably safe in the management of PsA patients with concomitant HCV infection. With regard to infliximab, efficacy and safety have been scarcely explored, whereas in the case of golimumab and certolizumab no report was found, may be due to their recent introduction on the market. SN - 1744-7682 UR - https://www.unboundmedicine.com/medline/citation/25652590/Current_evidence_in_the_field_of_the_management_with_TNF_α_inhibitors_in_psoriatic_arthritis_and_concomitant_hepatitis_C_virus_infection_ L2 - http://www.tandfonline.com/doi/full/10.1517/14712598.2015.1011616 DB - PRIME DP - Unbound Medicine ER -